Sunlenca Unia Europejska - polski - EMA (European Medicines Agency)

sunlenca

gilead sciences ireland unlimited company - lenacapavir sodium - infekcje hiv - Środki przeciwwirusowe do użytku ogólnoustrojowego - sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 i 5. sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 i 5.

Amvuttra Unia Europejska - polski - EMA (European Medicines Agency)

amvuttra

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - inne leki na układ nerwowy - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Sugammadex Amomed Unia Europejska - polski - EMA (European Medicines Agency)

sugammadex amomed

aop orphan pharmaceuticals gmbh - sugammadex sodium - blokada nerwowo-mięśniowa - wszystkie inne produkty terapeutyczne - odwrócenie blokady nerwowo-mięśniowej wywołanej rokuronium lub wekuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Piramal Unia Europejska - polski - EMA (European Medicines Agency)

sugammadex piramal

piramal critical care b.v. - sugammadex sodium - blokada nerwowo-mięśniowa - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

Sugammadex Adroiq Unia Europejska - polski - EMA (European Medicines Agency)

sugammadex adroiq

extrovis eu ltd. - sugammadex sodium - blokada nerwowo-mięśniowa - wszystkie inne produkty terapeutyczne - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.